盐酸安罗替尼治疗晚期非小细胞肺癌患者的临床疗效

The Clinical Efficacy of Anlotinib Hydrochloride in the Treatment of Advanced Non-Small Cell Lung Cancer Patients

目的:观察盐酸安罗替尼对晚期非小细胞肺癌患者临床疗效及生存质量的影响。方法:收集来我院就诊的诊断为非小细胞肺癌的患者66例,均采用盐酸安罗替尼进行治疗,1次/d,12mg/次,早餐前服用,然后对盐酸安罗替尼对本病患者治疗的临床疗效、生存质量和不良反应发生情况进行分析。结果:盐酸安罗替尼对本病的客观缓解率为34.8%,疾病控制率为89.4%,治疗后患者的日常生活得分、情绪控制得分、活动得分、社会/家庭生活得分和其他得分均高于治疗前,总得分(181.39±14.73)高于治疗前(160.73±12.16),差异具有统计学意义(P<0.05)。盐酸安罗替尼对非小细胞肺癌患者治疗后高血压的发生率最高,占13.6%,其次是手足综合征和甲状腺功能异常,分别占12.1%和9.1%,发生严重不良反应的患者6例,占9.1%。结论:盐酸安罗替尼对非小细胞肺癌治疗的疗效及安全性均有一定的优势,且可提高患者的生活质量,可为二、三线治疗失败及难治性患者提供治疗手段。

Objective:To observe the quality of life and clinical efficacy on anlotinib hydrochloride in the treatment of advanced non-small cell lung cancer patients.Methods:37 cases who were diagnosed with non-small cell lung cancer were collected from our hospital;anlotinib hydrochloride was administered to all patients,once a day,12 mg a time,before breakfast,then the clinical efficacy,effect on patients'quality of life,and adverse reactions of anlotinib hydrochloride in the treatment of this disease were analyzed.Results:The objective remission rate was 35.1%,while the disease control rate of anlotinib hydrochloride was 89.2%.After treatment,the scores of daily life,emotional control,activity,social/family life and other scores of patients were higher than before treatment,and the total score(181.39±14.73)after treatment was higher than before treatment(160.73±12.16).The differences were statistically significant(P<0.05).Anlotinib hydrochloride had the highest incidence of hypertension in patients with non-small cell lung cancer after treatment,accounting for 13.5%,followed by hand-foot syndrome and thyroid dysfunction,accounting for 10.8%and 8.1%,respectively.Six of the patients had serious adverse reactions,accounting for 8.1%.Conclusion:Anlotinib has certain advantages in the efficacy and safety of treatment of non-small cell lung cancer,and can improve the quality of life of patients,and it can provide treatment for patients with second-and third-line chemotherapy failure and the refractory.